Unexpected consequences of administering bacteriocinogenic probiotic strains for *Salmonella* populations, revealed by an *in vitro* colonic model of the child gut

Annina Zihler,1 Mélanie Gagnon,1 Christophe Chassard,1 Anita Hegland,1 Marc J. A. Stevens,1 Christian P. Braegger2 and Christophe Lacroix1

1Laboratory of Food Biotechnology, Institute of Food, Nutrition and Health, ETH Zürich, Zürich, Switzerland
2Division of Gastroenterology and Nutrition, University Children’s Hospital, Zürich, Switzerland

New biological strategies for the treatment of *Salmonella* infection are needed in response to the increase in antibiotic-resistant strains. *Escherichia coli* L1000 and *Bifidobacterium thermophilum* RBL67 were previously shown to produce antimicrobial proteinaceous compounds (microcin B17 and thermophilicin B67, respectively) active *in vitro* against a panel of *Salmonella* strains recently isolated from clinical cases in Switzerland. In this study, two three-stage intestinal continuous fermentation models of *Salmonella* colonization inoculated with immobilized faeces of a two-year-old child were implemented to study the effects of the two bacteriocinogenic strains compared with a bacteriocin-negative mutant of strain L1000 on *Salmonella* growth, as well as gut microbiota composition and metabolic activity. Immobilized *E. coli* L1000 added to the proximal colon reactor showed a low colonization, and developed preferentially in the distal colon reactor independent of the presence of genetic determinants for microcin B17 production. Surprisingly, *E. coli* L1000 addition strongly stimulated *Salmonella* growth in all three reactors. In contrast, *B. thermophilum* RBL67 added in a second phase stabilized at high levels in all reactors, but could not inhibit *Salmonella* already present at a high level (>10⁷ c.f.u. ml⁻¹) when the probiotic was added. Inulin added at the end of fermentation induced a strong bifidogenic effect in all three colon reactors and a significant increase of *Salmonella* counts in the distal colon reactor. Our data show that under the simulated child colonic conditions, the microcin B17 production phenotype does not correlate with inhibition of *Salmonella* but leads to a better colonization of *E. coli* L1000 in the distal colon reactor. We conclude that *in vitro* models with complex and complete gut microbiota are required to accurately assess the potential and efficacy of probiotics with respect to *Salmonella* colonization in the gut.

INTRODUCTION

The human gastrointestinal tract is colonized by a complex community of micro-organisms that plays a key protective role during enteric infections (Stecher & Hardt, 2008). Infectious gastroenteritis caused by non-typhoidal strains of *Salmonella enterica* subsp. *enterica* is an important cause of morbidity and mortality worldwide, especially in young children (Crum-Cianflone, 2008; Viswanathan et al., 2009). Due to an increasing incidence of antibiotic-resistant and more infective serovars (Kingsley et al., 2009), the use of probiotics with specific anti-*Salmonella* activities is of current interest. Mechanisms by which probiotics inhibit pathogens include competition for nutritional substrates and adhesion sites on intestinal epithelial cells, toxin inactivation, as well as the secretion of antimicrobial substances (Collado et al., 2009).

Bacteriocins are promising candidates as mediators of anti-pathogenic probiotic effects, and their ability to inhibit pathogens *in vitro* is well documented (Corr et al., 2009). Corr et al. (2007), for example, showed that *Lactobacillus salivarius* UCC118 is able to produce the bacteriocin Abp118 *in vivo*, resulting in the protection of mice against *Listeria monocytogenes* infection. Using an ICR mouse model infected with *Listeria*, Dabour et al. (2009) recently showed that intragastric administration of repeated doses of pediocin PA-1 reduces *Listeria* counts and pathogen translocation into the liver and spleen compared with the...
infected control group, leading to the disappearance of L. monocytogenes in these two organs within 6 days. However, enteric protection related to in situ bacteriocin production in human gut environments has been little studied.

Using simple in vitro activity tests, we recently showed that Escherichia coli L1000 producing microcin B17 is active against a broad panel of antibiotic-resistant and -sensitive Salmonella strains isolated in Switzerland from patients suffering from salmonellosis (Zihler et al., 2009). Furthermore, thermophilic B. thermophilum RBL67, a bacteriocin-like inhibitory substance produced by the Gram-positive bacterium Bifidobacterium thermophilum RBL67 (von Ah, 2006; von Ah et al., 2007), exerts strong inhibitory activity against 10 strains of the same panel belonging to six different serovars (our unpublished data). Although simple in vitro antagonist tests are useful for screening new probiotic bacteria with specific antimicrobial activity, gut environments are much more complex. Dynamic interactions between micro-organisms are responsible for colonization and competition, and in maintaining a healthy balance and the barrier effect of the gut microbiota in vivo. More elaborate models involving a complex gut microbiota providing conditions closer to those found in gastrointestinal environments are therefore required for activity and mechanistic studies of potential probiotics before considering more complex and expensive in vivo testing.

A single-stage continuous fermentation model for Salmonella colonization in the proximal colon that mimics long-term shedding in children was recently developed and used to compare the effects of antibiotic therapy and B. thermophilum RBL67 on salmonellosis in child gut environments (Le Blay et al., 2009; A. Zihler and others, unpublished results). B. thermophilum RBL67 grows in the intestinal environment and exhibits a strong inhibition of Salmonella when added before (preventive) or after (curative) Salmonella, and is able to rebalance the metabolic activity of gut microbiota after antibiotic treatments. These experiments were performed with S. enterica subsp. enterica serovar Typhimurium (S. Typhimurium) M557, a strain lacking Salmonella pathogenicity island (SPI)-1 effector proteins, and deficient in SPI-1- and SPI-2-dependent type III protein secretion systems that are known to be important host–microbe virulence factors of Salmonella (Hapfelmeier et al., 2004; Ohl & Miller, 2001).

In the present study, we tested the effects of a combined treatment with E. coli L1000 followed by B. thermophilum RBL67 on Salmonella growth, as well as gut microbiota composition and metabolic activity, using three-stage in vitro continuous gut fermentation models (Cinquin et al., 2006) that mimic the infected child colon, employing S. Typhimurium N-15, a highly invasive strain that was isolated from a clinical case (Zihler et al., 2009). E. coli L1000 was first tested by inoculating E. coli L1000 beads into the first reactor to model a colonizing E. coli strain, while the colonization and protective effect of E. coli L1000 was assumed to occur preferentially in the distal colon reactor, close to neutral pH. B. thermophilum RBL67 was inoculated in a second step to preferentially induce a protective effect in the proximal colon reactor at the lower pH of 5.7. Two three-stage models were operated in parallel to test comparatively the effects of E. coli L1000 wild-type (wt) producing microcin B17 and the bacteriocin-negative mutant E. coli L1000 MccB17−. Finally, a prebiotic treatment with inulin was tested to stimulate B. thermophilum RBL67 growth.

**METHODS**

**Bacterial strains.** S. Typhimurium N-15 was isolated in 2007 from an infected person in Switzerland and obtained from the National Center for Enteropathogenic Bacteria (NENT; Luzern, Switzerland). This strain was selected for its high invasion rate into mucus-secreting intestinal HT29-MTX cells compared with other Salmonella strains obtained from clinical cases, accompanied by a high disruption of epithelial integrity as revealed by transepithelial electrical resistance (TER) measurements (our unpublished data). It was routinely cultivated in tryptic soy broth (TSB; Difco) at 37 °C for 18 h.

E. coli L1000 wt was provided by Laves-Arzneimittel. E. coli L1000 MccB17−, lacking the microcin B17 phenotype, was constructed as described below. E. coli NCTC 50154, obtained from the UK National Collection of Type Cultures, was used as a microcin B17-sensitive indicator organism. E. coli strains were routinely grown on Luria–Bertani agar (LB; Becton Dickinson) for 18 h at 37 °C.

B. thermophilum RBL67 (our culture collection) was routinely grown at 37 °C for 18 h anaerobically in de Man Rogosa Sharpe broth supplemented with 0.05 % (w/v) L-cysteine HCl (MRSC; Sigma-Aldrich) in anaerobic jars with the AnaeroGen atmosphere generation system (Oxoid).

**Mutant construction.** The operon mcbABCDEFG, encoding microcin B17 production and immunity, was chosen as a target for gene deletion using the Quick & Easy E. coli Gene Deletion kit from Gene Bridges (BioCat) according to the manufacturer’s protocol. First, a PCR product of the FRT-PGK-gb2-neo-FRT cassette containing the flanking regions of mcbABCDEFG was amplified using the primers mcbA upper and mcbG lower (Table 1). The resulting 1737 bp product contained the FRT-PGK-gb2-neo-FRT cassette flanked by 50 bp up- and downstream regions of mcbABCDEFG introduced in the primers. The strain E. coli L1000 wt was transformed by electroporation with plasmid pRedET carrying the genes for recombination, resulting in strain E. coli L1000-pRedET. The linear FRT-PGK-gb2-neo-FRT-mcbABCDEFG fragment was transformed by electroporation into E. coli L1000-pRedET and after induction of recombination, primary integrants were selected on LB agar containing 15 µg kanamycin ml−1. Integrants were checked for site-specific integration by PCR using the primer pairs mcbA upper-control/Primer 2 (Table 1), annealing in the upstream and cassette promoter regions, and primer set Primer 3/mcbG lower-control, annealing in the downstream region and the kanamycin-resistance gene. The strain L1001, displaying the correct PCR profile, was cured according to the manufacturer’s protocol, resulting in the mcbABCDEFG-deletion strain E. coli L1000 MccB17−. The mutant was verified for a microcin B17-negative phenotype using a modified protocol of the double-agar layer assay described by Kheadr et al. (2010). Briefly, 2 µl of overnight cultures of E. coli L1000 wt and E. coli L1000 MccB17− were spotted onto the surface of LB agar (1.5 %, w/v) and plates were left to dry aseptically for 30 min. After incubation at 37 °C for 18 h, colonies were treated with 10 µl chloroform (Sigma-Aldrich) for 1 min in closed Petri dishes and subsequently dried in opened dishes. A second layer of 15 ml LB agar (0.8 %, w/v) seeded with 1 % (v/v) of an
Table 1. Primers and probes used for the construction of the mutant *E. coli* L1000 *MccB17*– and the detection of different bacterial groups in faecal microbiota by real-time qPCR analysis

<table>
<thead>
<tr>
<th>Target</th>
<th>Primer or probe</th>
<th>Sequence (5’–3’)</th>
<th>Source or reference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mutant construction</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Upstream of <em>mcbA</em> (underlined)</td>
<td>mcbA upper</td>
<td>ACG GCA AGT AAC TAG TGT TGG CCA ACA TAC TAT TCA GAT</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GTC ATA AGC AGC ATT AAC CCT CAC TAA AGG GCG</td>
<td></td>
</tr>
<tr>
<td></td>
<td>mcbA upper-control</td>
<td>CAG GCG TAC AAA TTT AGT TC</td>
<td>This study</td>
</tr>
<tr>
<td>Downstream of <em>mcbG</em> (underlined)</td>
<td>mcbG lower</td>
<td>ATC GAG ATG GAG AAC TCA GTC AAT GGT CCA TTC TTT CTG</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AAA TAT GTG TGT AAT ACG ACT CAC TAT AGG GCT C</td>
<td></td>
</tr>
<tr>
<td>Upstream of the 5’ integration site of <em>mcbABCDEFG</em></td>
<td>mcbA upper-control</td>
<td>CAG GCG TAC AAA TTT AGT TC</td>
<td>This study</td>
</tr>
<tr>
<td>Downstream of the 3’ integration site of <em>mcbABCDEFG</em></td>
<td>mcbG lower-control</td>
<td>CTC AAA ATG CTC GGA TAC CC</td>
<td>This study</td>
</tr>
<tr>
<td>Promoter region of the cassette (reverse)</td>
<td>Primer 2</td>
<td>CGA GAC TAG TGA GAC GTG CTA C</td>
<td>*</td>
</tr>
<tr>
<td>Kanamycin-resistance gene of the cassette (forward)</td>
<td>Primer 3</td>
<td>TAT CAG GAC ATA GCG TTT GCT ACC</td>
<td>*</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Real-time qPCR</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All bacteria</td>
<td>Eub338F</td>
<td>ACT CCT ACG GGA GGC AG</td>
<td>Guo <em>et al.</em> (2008)</td>
</tr>
<tr>
<td></td>
<td>Eub518R</td>
<td>ATT ACC GCG GCT GCT GG</td>
<td></td>
</tr>
<tr>
<td>Bacteroides spp.</td>
<td>Bac303F</td>
<td>GAA GGT CCC CCA CAT TG</td>
<td>Ramirez-Farias <em>et al.</em> (2009)</td>
</tr>
<tr>
<td></td>
<td>Bfr-Fmrev</td>
<td>CGC KAC TATG CCA CGG TCA G</td>
<td></td>
</tr>
<tr>
<td>Bifidobacterium spp.</td>
<td>xfp-fw</td>
<td>ATC TCT GGA CCB GAY GAG AC</td>
<td>Cleusix <em>et al.</em> (2010)</td>
</tr>
<tr>
<td></td>
<td>xfp-rv</td>
<td>CGA TVA CGT GVA CGG AGG AC</td>
<td></td>
</tr>
<tr>
<td><em>B. thermophilum</em></td>
<td>bthermRTF</td>
<td>TTG CTT GCG GGT GAG AG</td>
<td>Mathys <em>et al.</em> (2008)</td>
</tr>
<tr>
<td></td>
<td>bthermRTR</td>
<td>CGC CAA CAA GCT GAT AGG AC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>bthermTqM</td>
<td>†FAM-ATG TGC CGG GCT CCT GCA T†TAMRA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eco1652R</td>
<td>CTC TAC GGA ACT CAA GCT TGC</td>
<td></td>
</tr>
<tr>
<td><em>E. coli</em> L1000 <em>wt</em></td>
<td>mcbAF</td>
<td>CAC GCC AGT CTC CAT TAG GT</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>mcbAR</td>
<td>CCG TTT CCA CCA CTA CAA CC</td>
<td></td>
</tr>
<tr>
<td><em>E. coli</em> L1000 <em>MccB17</em>–</td>
<td>mcbAFMut</td>
<td>TTG GCC AAC ATA CTA TTC AGA TG</td>
<td>This study</td>
</tr>
<tr>
<td></td>
<td>mcbARMut</td>
<td>GAC TCA CTA TAG GGC TCG AGG A</td>
<td></td>
</tr>
<tr>
<td>Lactobacillus/Leuconostoc/Pediococcus spp.</td>
<td>F_Lacto 05</td>
<td>AGC AGT AGG GAA TCT TCC A</td>
<td>Furet <em>et al.</em> (2009)</td>
</tr>
<tr>
<td></td>
<td>R_Lacto 04</td>
<td>CGC CAC TGG TGT TCT TCC ATA TA</td>
<td></td>
</tr>
</tbody>
</table>

*Primers were provided within the Quick & Easy *E. coli* Gene Deletion kit (Gene Bridges GmbH).
†FAM, 6-carboxyfluorescein (fluorescent reporter dye); TAMRA, 6-carboxytetramethylrhodamine (quencher).
E. coli three-stage fermentation systems. Faecal beads was immediately transferred to the first reactors of both within 3 h after defecation. An inoculum of 60 ml (30%, v/v) of fresh 2009). The entire process was performed under anaerobic conditions absence of inhibition zones.

Bacterial immobilization. A faecal sample (~5 g) from a healthy 2-year-old child (male), receiving a fully diversified diet and not exposed to antibiotic therapy for at least 3 months before the experiment, was collected. The sample was transferred to a tube containing 5 ml sterile, pre-reduced peptone water (0.1%, pH 7), placed in an anaerobic jar, and immediately delivered to the laboratory before being homogenized. The faecal suspension was weighed and the volume adjusted with peptone water to obtain a final faecal concentration of 20% (w/v). The faecal bacterial extract was immobilized in 1–2 mm diameter gel beads composed of 2.5% gellan gum, 0.25% xanthan gum and 0.2% sodium citrate (w/v, Sigma-Aldrich), as described previously (Cleusix et al., 2008; Le Blay et al., 2009). The entire process was performed under anaerobic conditions within 3 h after defecation. An inoculum of 60 ml (30%, v/v) of fresh faecal beads was immediately transferred to the first reactors of both three-stage fermentation systems.

Ten-fold-concentrated overnight cultures of S. Typhimurium N-15, E. coli L1000 wt, E. coli L1000 MccB17– and B. thermophilum RB67 were separately immobilized in the same way but aerobically. Bead colonization was performed with batch cultures in TSB for Salmonella (18 h, 37 °C, no pH control), in LB for E. coli (18 h, 37 °C, no pH control) and in MRSC for B. thermophilum RB67 (24 h, 40 °C, pH 6.0, stirring at 150 r.p.m.). Colonized beads were washed in sterile CaCl₂ (0.1 mol L⁻¹) and used to inoculate the first or third reactor of the appropriate fermentation system, as described below.

Nutritive culture medium. A complex culture medium simulating the intestinal chyme of a young child was used to feed the first reactor of each three-stage fermentation system. The medium was similar to that described by Macfarlane et al. (1998) and modified for children by reducing the bile salt concentration from 0.4 to 0.05 g l⁻¹ in order to reproduce the ileal chyme of a young child (Le Blay et al., 2009). A 0.5 ml volume of a filter-sterilized (Minisart, 0.2 μm pore-size, Sartorius) vitamin solution (Michel et al., 1998) was added to 1 L of the autoclaved (15 min, 121 °C) medium. For prebiotic treatments, the medium was supplemented with 15 g l⁻¹ high-solubility inulin (Orafi HIS, Beneo Orafi) before autoclaving.

Fermentation procedures. Faecal bead colonization was performed during batch fermentations for 48 h in two reactors (Sixfors, Infors) containing 30% fresh beads and operated at a working volume of 200 ml at pH 5.7 and 37 °C, as previously described (Le Blay et al., 2009). The fermented medium was replaced every 12 h with fresh nutritive medium. Then, two additional reactors (R2 and R3), half-filled with sterile nutritive medium, were connected in series to the first reactor, R1. Continuous fermentation was started by connecting a stirred feedstock vessel containing sterile nutritive medium (4 °C) via peristaltic pumps (Reglo Analog, Ismatec) to R1. Fermented medium from R1 was then pumped to R2 (working volume 400 ml), from R2 to R3 (working volume 400 ml), and finally from R3 to an effluent receiving vessel. The retention times and pH in R1, R2 and R3 were selected to mimic in vivo conditions in the child proximal, transverse and distal colons (Fallingborg et al., 1990; Wagener et al., 2004). The total mean retention time of the system with a total volume of 800 ml was set at 25 h by adjusting the feed flow rate to 40 ml h⁻¹, resulting in mean retention times of 5 h for R1 and 10 h for R2 and R3. The headspace of the reactors were continuously flushed with CO₂ to maintain anaerobic conditions. The pH in R1, R2 and R3 was automatically controlled at pH 5.7, 6.2 and 6.7, respectively, by adding 5 M NaOH.

The two three-stage reactor models (F1 and F2) were operated in parallel for a total of 65 days, which was divided into different periods, as shown in Fig. 1. After bead colonization and stabilization for 10 days (Stab), S. Typhimurium N-15 beads (2.3 × 10⁶ c.f.u. g⁻¹) were added twice to the first reactor (R1) of both models (2 g on day 13 and 2.5 g on day 17) to induce Salmonella colonization. Continuous culture was carried out until day 22 (Sal), Beads containing the microcin B17-producing wild-type strain of E. coli (L1000 wt) were added on day 22 to R1 of F1 (5 g, 1.5 × 10⁶ c.f.u. g⁻¹, Ecol I) and repeated on day 36 in R3 (5 g, 1.4 × 10⁶ c.f.u. g⁻¹, Ecol II). For F2, the same protocol was applied but the wild-type E. coli strain was replaced by the mutant E. coli L1000 MccB17–, which did not produce microcin B17. On day 44, 5 g B. thermophilum RB67 beads (3.4 × 10⁹ c.f.u. g⁻¹) were added to R1 of both models (F1, Bif I; F2, Bif I). This treatment was repeated on day 56 in the first fermentation model (F1, Bif I), while in the second fermentation model (F2), the nutritive medium was supplemented instead with 15 g inulin per day during the last fermentation period (Inulin). Effluents (13 ml) were simultaneously sampled daily in the morning from each reactor and processed within 1 h for the enumeration of S. Typhimurium N-15 by selective plating and of bacterial populations by real-time quantitative PCR (real-time qPCR) analysis, and for HPLC measurements.

Salmonella enumeration by plate counts. Serial 10-fold dilutions of effluent samples were carried out in peptone water (0.1%, pH 7.0) and plated daily in duplicate on CHROMagar Salmonella medium (Becton Dickinson). Plates were incubated aerobically at 37 °C for 48 h.

Fermentation 1 (F1)

**Fig. 1.** Experimental design for continuous intestinal fermentations. Stab, stabilization; Sal, S. Typhimurium N-15; Ecol I and Ecol II, E. coli L1000 wt; Ecol I and Ecol II, E. coli L1000 MccB17–; Bif I and Bif II, B. thermophilum RB67; Inulin, inulin period. †Addition of S. Typhimurium N-15 beads; §addition of E. coli L1000 beads; ‡addition of B. thermophilum RB67 beads.

http://mic.sgmjournals.org
Analysis of gut microbiota populations using real-time qPCR.

Genomic DNA was extracted from 1.5 ml effluent samples with the FastDNA SPIN Kit for Soil (MP Biomedicals) according to the manufacturer’s instructions, with a final elution volume of 100 μl. Primer sets used for different bacterial groups in this study (Microsynth) are listed in Table 1. Primers used for the enumeration of *E. coli* L1000 wt and *E. coli* L1000 *MccB17*– were designed using the Primer3 Input software (version 0.4.0; http://frodo.wi.mit.edu/primer3) based on the *mcbABCDEFEG* operon sequence (EMBL accession no. FM877811) and the sequence in the mutant strain after removal of the selection marker. Primers were checked for *T_m* (melting temperature), secondary structure formation, G+C content and primer–dimer formation using the PCR Primer Stats software (http://www.bioinformatics.org/sms2/pcr_primer_stats.html).

PCR amplification and detection were performed with an ABI PRISM 7500-PCR sequence detection system (Applied Biosystems) in MicroAmp Fast Optical 96-Well Reaction Plates with Barcode (Applied Biosystems). Each reaction was run in duplicate and took place in a total volume of 25 μl, containing 12.5 μl 2× SYBR Green PCR Master Mix (Applied Biosystems), 0.2 μmol l⁻¹ of the appropriate primers, and 1 μl template DNA diluted 10- or 100-fold depending on the targeted bacterial group. For the detection of *B. thermophilum* RBL67, reaction mixtures were composed of 12.5 μl qPCR MasterMix Plus LowRox (Eurogentec), 2.5 μl template DNA diluted 10-fold, 0.3 μmol l⁻¹ of each primer and 0.1 μmol l⁻¹ TaqMan probe. Real-time qPCR conditions were kept at the pre-settings of the ABI PRISM 7500-PCR sequence detection system, with an initial heating step of 2 min at 50 °C and a denaturation step of 10 min at 95 °C, followed by 40 amplification cycles of 95 °C for 15 s and 60 °C for 1 min. A final dissociation step was added for SYBR Green amplifications to improve amplification specificity. The fluorescent products were detected during the second step of each cycle. Melting curve analysis was performed after amplification using the 7500 Fast system SDS Software (version 1.4, Applied Biosystems) to evaluate the specificity of the primers and quality of the PCR. A standard curve for each primer pair was analysed in the same run and used for calculation of the number of 16S rDNA or gene copies in the 7500 Fast system SDS Software (version 1.4, Applied Biosystems) in effluent samples before addition to F1 and F2, respectively. After adding 5 g *E. coli* L1000 wt (F1) and *MccB17*– (F2) beads to R1 (Ecol I and Ecol*I), MCN values were 1–1.5 log units higher for *E. coli* L1000 wt compared with *MccB17*–, which was significant only in R2 and R3 (*P*<0.05). A second addition of *E. coli* L1000 beads to R3 in both systems led to a significant (*P*<0.011) increase of *E. coli* L1000 counts in the effluent of R3 only for the mutant strain *MccB17*– (F2), with no effect for *E. coli* L1000 wt. Counts of *E. coli* L1000 wt decreased in both R1 and R2, and increased in R3 (*P*<0.05) by approximately 1 log unit after adding *B. thermophilum* RBL67 to R1 (Bif I). In contrast, no change of *E. coli* L1000 counts was observed for the mutant strain *MccB17*– (Bif in...
F2) and after a second addition of *B. thermophilum* RBL67 to R1 (Bif II in F1). Inulin addition (‘Inulin’ in F2) induced a decrease of *E. coli* L1000 MccB17− counts in R1 and R2 (only significant for R1), with no change recorded in F3.

*B. thermophilum* RBL67 was not detected in effluent samples of F1 and F2 before addition to R1. After adding 5 g *B. thermophilum* RBL67 beads to R1, counts of *B. thermophilum* RBL67 reached similar high values in all reactors of F1 and F2, with respective mean values for log10(MCN ml−1) of 6.5 ± 0.4 (Bif I) and 6.5 ± 0.1 (Bif).

Asterisks signify that means for the corresponding periods of F1 and F2 are significantly different with the *F* test.

---

**Fig. 4.** Mean concentrations of *Bifidobacterium* spp. (■, ○) and *B. thermophilum* RBL67 (●, ◊) in effluent samples of the proximal (R1), transverse (R2) and distal (R3) colon reactors of F1 (filled symbols) and F2 (open symbols) measured by real-time qPCR, expressed as log10(MCN ml−1) (mean of last 3 days of the period). Period means with different letters are significantly different within F1 (roman type) and F2 (italic type), respectively, with the Tukey–Kramer HSD test (*P* < 0.05). Effects of two probiotic strains in a colonic model
Effects of probiotic and prebiotic treatments on Salmonella propagation

Daily Salmonella concentrations determined by selective plating during 65-day fermentations in F1 and F2 are presented in Fig. 5, and mean concentrations detected during the last 3 days of each fermentation period are displayed in Table 2. After the first addition of 2 g S. Typhimurium N-15 beads, Salmonella was detected in the effluents of all reactors after 1 day but decreased steadily thereafter. A second addition of 2.5 g S. Typhimurium N-15 beads was performed and a continuous increase of Salmonella counts was recorded in all reactors of F1 and F2, reaching at the end of the Salmonella stabilization period (Sal) higher levels in R1 and R2 compared with R3, with means of 5.8 ± 0.3, 5.6 ± 0.5 and 4.3 ± 0.5 log c.f.u. ml⁻¹, respectively.

Effects of E. coli L1000. The addition of 5 g E. coli L1000 wt or MccB17⁻ beads to R1 further stimulated Salmonella growth during the following 14-day period in F1 and F2 (Fig. 5). Salmonella counts increased linearly with time (P<0.0001) in all reactors, with a higher rate in R2 compared with R1 and R3 for both models. A second addition of 5 g E. coli L1000 beads in the distal reactor (R3) of F1 and F2 on day 36 had no significant effect on Salmonella counts in the reactor effluent (Ecol II and Ecol*II). After E. coli L1000 addition, Salmonella counts in

![Fig. 5.](Image)

Salmonella concentrations, as log₁₀[c.f.u. (ml effluent)]⁻¹, measured daily by plate counts in effluents of the proximal (R1), transverse (R2) and distal (R3) colon reactors of fermentations F1 and F2. Regression lines were calculated over the time period from day 14 to 37 for F1 (solid lines) and F2 (dashed lines). * and §, addition of 5 g E. coli L1000 wt and E. coli L1000 MccB17⁻ beads to F1 and F2, respectively; †addition of 5 g B. thermophilum RBL67 beads; ‡addition of 5 g B. thermophilum RBL67 beads to F1 and start of nutritive medium supplementation with inulin (15 g per day) for F2.
Table 2. *Salmonella* counts [log_{10}(c.f.u. ml^{-1})] obtained by selective plating on CHROMagar *Salmonella* medium for different fermentation periods of continuous cultures in F1 and F2.

Data are reported as mean ± SD of three reactors for the last 3 days. Values with different letters in a column are significantly different by the Tukey–Kramer HSD test or the F test (P<0.05). ND, Not detected.

<table>
<thead>
<tr>
<th>Period</th>
<th>R1</th>
<th>R2</th>
<th>R3</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stab</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sal</td>
<td>5.6 ± 0.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>5.9 ± 0.2&lt;sup&gt;c&lt;/sup&gt;</td>
<td>4.7 ± 0.1&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol I</td>
<td>6.8 ± 0.4&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>7.6 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.3 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol II</td>
<td>6.5 ± 0.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>7.3 ± 0.1&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>6.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bif I</td>
<td>7.2 ± 0.2&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>6.8 ± 0.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>6.1 ± 0.6&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bif II</td>
<td>7.3 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.1 ± 0.1&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>6.3 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>F2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stab</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Sal</td>
<td>6.0 ± 0.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5.3 ± 0.6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.0 ± 0.4&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol&lt;sup&gt;II&lt;/sup&gt;I</td>
<td>6.6 ± 0.1&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>7.1 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.0 ± 0.3&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol&lt;sup&gt;II&lt;/sup&gt;II</td>
<td>6.4 ± 0.2&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>7.2 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.3 ± 0.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bif</td>
<td>6.9 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.8 ± 0.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.5 ± 0.3&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Inulin</td>
<td>6.8 ± 0.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.9 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.2 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Effects of *B. thermophilum* RBL67. Addition of 5 g *B. thermophilum* RBL67 beads on day 44 to R1 showed no significant effects on *Salmonella* counts in all three reactors of F1 and F2, which were in the range from 6.1 ± 0.6 to 7.2 ± 0.2 log_{10}(c.f.u. ml^{-1}) during the last 3 days of the Bif I (F1) and Bif (F2) periods (Table 2). Subsequent addition of 5 g *B. thermophilum* RBL67 beads to R1 on day 55 had no significant effect on *Salmonella* counts (Bif II, F1) compared with the previous Bif I period.

Effects of inulin. Supplementation of the nutritive medium with inulin during the final experimental period of F2 (Inulin) led to significantly (P=0.037) increased levels of *Salmonella* in R3, with no detectable effects in R1 and R2.

Effects of *Salmonella*, probiotic and prebiotic treatments on main gut microbiota populations

MCN (ml effluent)^{-1} values of intestinal populations measured by real-time qPCR during the last 3 days of each experimental period were not significantly different for the proximal, transverse and distal reactors. Therefore, the mean MCN values calculated for the three reactors are presented in Table 3.

Independent of the experimental period, high and stable counts of total bacteria were detected in all reactors of both models, with high values in the range 2.6 × 10^{10}–5.8 × 10^{10} and 1.5 × 10^{10}–4.7 × 10^{10} MCN ml^{-1} measured for F1 and F2, respectively, during 65 days of continuous culture. *Bacteroides* spp. was the predominant bacterial group, followed by *Enterobacteriaceae*, *Bifidobacterium* spp. and *Lactobacillus/Leuconostoc/Pediococcus* spp. Counts of *Bacteroides* spp. were stable overall during the experiment in F1 and F2, except for the final inulin period in R1 of F2.

Table 3. log_{10}(MCN ml^{-1}) values for intestinal populations measured by real-time qPCR in faecal inoculum and fermentation effluent samples for different periods of fermentations F1 and F2.

Data are means ± SD of three reactors calculated for the last 3 days of each fermentation period. Values with different letters in a column of the same reactor are significantly different by the Tukey–Kramer HSD test (P<0.05).

<table>
<thead>
<tr>
<th>Period</th>
<th>Total bacteria</th>
<th>Bacteroides spp.</th>
<th>Bifidobacterium spp.</th>
<th>Lactobacillus/Leuconostoc/Pediococcus spp.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faeces</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>F1</td>
<td>10.7</td>
<td>10.1</td>
<td>7.6</td>
<td>5.1</td>
</tr>
<tr>
<td>Stab</td>
<td>10.4 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.5 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.2 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.4 ± 0.3&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sal</td>
<td>10.5 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.6 ± 0.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>7.2 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.4 ± 0.5&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol I</td>
<td>10.5 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.6 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>7.0 ± 0.3&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>5.4 ± 0.6&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol II</td>
<td>10.5 ± 0.1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.6 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.7 ± 0.2&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>6.0 ± 0.3&lt;sup)b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bif I</td>
<td>10.6 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.7 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.8 ± 0.3&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>5.7 ± 0.3&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bif II</td>
<td>10.5 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.6 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.4 ± 0.2&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>6.7 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>F2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stab</td>
<td>10.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.4 ± 0.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>6.9 ± 0.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.2 ± 0.3&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Sal</td>
<td>10.5 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.4 ± 0.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>6.6 ± 0.4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.3 ± 0.6&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol&lt;sup&gt;II&lt;/sup&gt;I</td>
<td>10.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.4 ± 0.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.5 ± 0.2&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>5.1 ± 0.5&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Ecol&lt;sup&gt;II&lt;/sup&gt;II</td>
<td>10.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.5 ± 0.4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.1 ± 0.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>5.1 ± 0.8&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td>Bif</td>
<td>10.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.6 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.5 ± 0.4&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>5.9 ± 0.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Inulin</td>
<td>10.4 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.1 ± 0.9&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8.3 ± 0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>8.1 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

*log_{10}(MCN ml^{-1}) values were significantly lower in R1 (8.0 ± 0.4) than in R2 (9.7 ± 0.3) and R3 (9.8 ± 0.1).
where a significant \((P=0.001)\) decrease from \(9.4 \pm 0.4\) to \(7.9 \pm 0.4\ \log_{10}(\text{MCN} \text{ ml}^{-1})\) was measured. MCN ranges of bacterial groups measured during Stab in the effluents of the different reactors were similar to those of the faecal inoculum, except for \textit{Enterobacteriaceae}, for which the MCN values were about 3 log units higher than for the faecal inoculum.

\textit{Salmonella} addition to F1 and F2 had no significant \((P>0.05)\) effects on \textit{Bifidobacterium} spp. and \textit{Enterobacteriaceae} populations, but was accompanied by a significant increase of \textit{Lactobacillus/Leuconostoc/Pediococcus} spp. counts, from \(3.4 \pm 0.3\) (Stab) to \(4.4 \pm 0.5\) (Sal) \(\log_{10}(\text{MCN} \text{ ml}^{-1})\) in F1 \((P=0.003)\) and from \(3.2 \pm 0.3\) (Stab) to \(4.3 \pm 0.6\) (Sal) \(\log_{10}(\text{MCN} \text{ ml}^{-1})\) in F2 \((P=0.012)\).

**Effects of \textit{E. coli} L1000.** No significant \((P>0.05)\) changes of \textit{Bifidobacterium} spp. and \textit{Enterobacteriaceae} populations were measured during the first \textit{E. coli} L1000 treatments [Ecol I (F1) and Ecol*I (F2)], and MCN values of \textit{E. coli} L1000 were 3–5 log units lower compared with total \textit{Enterobacteriaceae}. MCN values for \textit{Lactobacillus/Leuconostoc/Pediococcus} spp. increased significantly \((P<0.0001)\) with the first addition of \textit{E. coli} L1000 wt (F1, +1 log unit) or \textit{MccB17}− (F2, +0.8 log unit) to levels similar \((P>0.05)\) to those measured in the faecal inoculum \([5.1 \log_{10}(\text{MCN} \text{ ml}^{-1})]\). No significant population changes were detected after the second addition of \textit{E. coli} L1000, except for a small but significant \((P=0.032)\) increase of \textit{Enterobacteriaceae} from \(8.3 \pm 0.3\) (Ecol*I) to \(8.7 \pm 0.2 \log_{10}(\text{MCN} \text{ ml}^{-1})\) (Ecol*II) in F2.

**Effects of \textit{B. thermophilum} RBL67.** The first addition of \textit{B. thermophilum} RBL67 to F1 (Bif I) and F2 (Bif) had no significant \((P>0.05)\) effects on \textit{Bifidobacterium} spp. and \textit{Enterobacteriaceae} populations. Counts of \textit{B. thermophilum} RBL67 during these periods were equal to total \textit{Bifidobacterium} spp. counts. \textit{Lactobacillus/Leuconostoc/Pediococcus} counts increased significantly \((P=0.032)\) only in F2 compared with the previous Ecol*II period, and stabilized at \(5.8 \pm 0.3 \log_{10}(\text{MCN} \text{ ml}^{-1})\) (Bif I, Bif) in both F1 and F2. In contrast, the second addition of \textit{B. thermophilum} RBL67 in F1 (Bif II) was accompanied by a small \((P=0.029)\) decrease of \textit{Bifidobacterium} spp. from \(6.8 \pm 0.3\) (Bif I) to \(6.4 \pm 0.2\) (Bif II) \(\log_{10}(\text{MCN} \text{ ml}^{-1})\) and a significant \((P<0.0001)\) increase of \textit{Lactobacillus/Leuconostoc/Pediococcus} spp. from \(5.7 \pm 0.3\) (Bif I) to \(6.7 \pm 0.2\) (Bif II) \(\log_{10}(\text{MCN} \text{ ml}^{-1})\).

**Effects of inulin.** Inulin addition to F2 resulted in a sharp and significant \((P<0.0001)\) increase of both \textit{Lactobacillus/Leuconostoc/Pediococcus} spp. and \textit{Bifidobacterium} spp. populations \([>2\) and \(1.5 \log_{10}(\text{MCN} \text{ ml}^{-1})\], respectively, in all reactors], concomitant with \textit{B. thermophilum} RBL67 counts.

**Effects of probiotic and prebiotic treatments on gut metabolic activity**

No periodic effects (except for inulin addition) were detected on SCFA concentrations and ratios measured by HPLC. Therefore, mean SCFA concentrations and ratios calculated for the last 3 days of each experimental period for different reactors are presented in Table 4. Stable levels of total SCFA concentrations were measured in all reactors for both F1 and F2, with increasing values from the proximal (R1) to the distal (R3) colonic reactors. SCFA concentrations and ratios were similar for F1 and F2 (with the exception of the last inulin period; Table 4). Inulin addition in F2 led to a significant \((P<0.05)\) increase in butyrate from \(46.8 \pm 0.9, 54.3 \pm 1.5\) and \(52.4 \pm 0.5\ mmol l^{-1}\) to \(88.4 \pm 1.8, 105.1 \pm 6.0\) and \(101.1 \pm 3.8\ mmol l^{-1}\) in R1, R2 and R3, respectively. Butyrate accounted for approximately 50% of total SCFA compared with only 35% during the previous Bif period. A concomitant reduction in proportion of acetate from 56 to 44% was measured, whereas propionate remained unchanged.

**DISCUSSION**

The development of biological alternatives to antibiotics in order to treat infections and address the increasing
prevalence of antibiotic-resistant and highly invasive pathogenic bacteria is of high public interest. Probiotic bacteria have great potential to complement or substitute conventional antibiotic treatments. Beneficial properties such as anti-Salmonella activity are, however, strain-specific and must be assessed separately for each probiotic bacterium. Two promising probiotic strains isolated from human faeces were tested in this study, E. coli L1000 and B. thermophilum RBL67 (von Ah et al., 2007; Zihler et al., 2009). These have been shown to produce proteinaceous antimicrobial compounds with high and broad activity against Salmonella when assessed with simple antagonistic tests.

The human colon constitutes a protective and nutrient-rich habitat for trillions of bacteria living in symbiosis with the host (Gaskins et al., 2008). This dense and host-dependent microbial community has established an ecological mutualism with the host that confers a powerful barrier effect against pathogenic invaders, referred to as colonization resistance (Barth et al., 2009). The ability to protect the host from invading pathogens presupposes that probiotics are able to transiently occupy a specific ecological niche in adequate numbers for optimal functionality. Barth et al. (2009) were able to show recently that the probiotic E. coli strain Nissle 1917 producing colicin has the capacity to adapt easily to the intestinal milieu of healthy conventional piglets, allowing persistence and replication in the gut. There are, however, no studies investigating the competitiveness of bacteriocinogenic strains compared with negative mutants for intestinal colonization and efficacy to counteract pathogens. In our study, E. coli L1000, independently of the presence of genetic determinants for microcin B17 production, was not able to colonize in vitro a complex gut microbiota at a high level \( \leq 5.8 \log_{10}(MCN \, ml^{-1}) \) during the Ecol periods, even after high inoculation with \( 6 \times 10^8 \) cells immobilized in beads to induce colonization. This addition considerably exceeds the colonic delivery of probiotics at the recommended daily dose of \( 10^8-10^9 \) cells believed to exert a beneficial effect on the host (Gill & Prasad, 2008), while accounting for the potentially high viability loss during passage through the upper gastrointestinal tract. Accordingly, E. coli L1000 addition did not significantly affect gut microbiota composition or metabolic activity, except for an increase of the Lactobacillus/Leuconostoc/Pediococcus population, although it strongly stimulated Salmonella growth. It has been previously shown that addition of Salmonella to a proximal reactor of an in vitro intestinal colonic fermentation model with immobilized child faecal microbiota stimulates the growth of the Clostridium coccoides–Eubacterium rectale group (Le Blay et al., 2009), which also belongs to the phylum Firmicutes. The inability of E. coli L1000 to stabilize at high levels in our model could also be explained by the high levels of Enterobacteriaceae with similar environmental requirements in the intestinal ecosystem of the donor. Microcin B17 production did not confer a significant ecological advantage upon E. coli L1000 wt over other Enterobacteriaceae, although microcin B17 has been shown to be active against Salmonella and other Enterobacteriaceae (Pons et al., 2002). However, the E. coli L1000 wt population was significantly higher in R2 and R3 after the first inoculation of the strain in R1 (Ecol I) compared with the bacteriocin-negative mutant (Ecol*), possibly due to in situ microcin B17 production. Stecher et al. (2010) have recently provided evidence that the presence of closely related strains can enhance the possibility of invasion of exogenous bacteria into the gut ecosystem. Mice harbouring high levels of gut lactobacilli are more efficiently colonized by a commensal and orally administered Lactobacillus reuteriRR strain. In addition, those authors provide evidence that individuals with high commensal Enterobacteriaceae densities are more susceptible to Salmonella-induced gut inflammation. Our data that show a stimulation of Salmonella growth after addition of E. coli L1000 to a gut microbiota already highly colonized with Enterobacteriaceae support this mechanism.

In contrast to E. coli L1000, B. thermophilum RBL67 colonized the intestinal microbiota at high levels after the first addition and accounted for a very high proportion (\( \geq 70 \% \)) of the total bifidobacteria population. In a previous study, we showed that B. thermophilum RBL67 added to a reactor simulating a child proximal colon made up to 12\% of total bifidobacteria (A. Zihler and others, unpublished results). Although the metabolic activity and composition of the intestinal ecosystem were little changed upon B. thermophilum RBL67 addition, a significant decrease in bifidobacteria counts was observed, possibly explained by thermophilicin B67 production affecting closely related bacteria. In addition, B. thermophilum RBL67 was highly active against S. Typhimurium M557, when added to the reactor preventively before or curatively after Salmonella colonization. Compared with the present study, Salmonella counts were about 1.5 log units lower before the addition of strain RBL67. Therefore, very different B. thermophilum RBL67: Salmonella ratios (3050:1 and 2:1, respectively) were reached. The determination of the required probiotic dose for a targeted anti-pathogenic effect is difficult because the optimal concentration depends on several factors, including the probiotic organism, duration of application, delivery matrix (food or pharmaceutical) and the targeted population group (de Vrese & Schrezenmeir, 2008). For example, a dose-efficacy study revealed that a 1-week Lactobacillus rhamnosus GG (LGG) treatment was equally effective at two dosages (\( 10^{10} \) and \( 10^{12} \) c.f.u. twice per day) in decreasing the frequency and duration of rotavirus-induced acute watery diarrhoea in Indian children (Basu et al., 2009), although data on the LGG:rotavirus ratios in the gut are lacking. To our knowledge, no study has investigated probiotic: pathogen ratios in the gut for maximal enteric protection, especially against Salmonella.

Inulin addition produced a large increase of lactobacilli counts and a pronounced bifidogenic effect accompanied by a shift in SCFA ratios towards elevated butyrate levels, as observed in previous studies (Kleessen et al., 2001;
Langlands et al., 2004; Le Blay et al., 2009). Interestingly, addition of inulin also led to a sharp increase of B. thermophilaum RBL67 counts in all three reactors, and stimulated the growth of Salmonella in the distal colon reactor R3. Several studies have reported a correlation between the administration of different prebiotics (including inulin) and an enhanced severity of Salmonella infection in rats and mice (Bovee-Oudenhoven et al., 2003; Petersen et al., 2009; Ten Bruggencate et al., 2003, 2004) with increased translocation of Salmonella, although these effects are not always correlated with an enhanced pathogen colonization of the gut.

In conclusion, data obtained with our in vitro intestinal fermentation model of Salmonella colonization in the child colon reflect a lack of efficacy of microcin B17-producing E. coli L1000 to inhibit Salmonella, in contrast to the high efficacy displayed by this strain in simple in vitro antagonistic tests (Zihler et al., 2009). Although simple in vitro activity assays are practical and useful for first screening of probiotics active against Salmonella, more complete models reflecting the complex gut microbiota and environments are required to assess their efficacy and provide information on the mechanisms of probiotics for enteric protection within a complex microbial ecosystem. This validation step is important before considering in vivo testing with animal models. Indeed, several biotic factors are difficult to reproduce in vitro, and especially host immune and neuroendocrine responses are lacking in in vitro colonic fermentation models. Therefore, we are currently testing with intestinal epithelial cell models the in vitro effects on the host cell response of effluent samples produced by the colonic fermentation model and containing a child gut microbiota, Salmonella and probiotics. Such combined in vitro models could provide a more complete assessment of the potential and mechanisms of probiotics against pathogen infection in the gut.

ACKNOWLEDGEMENTS

This study was supported by a grant from the Swiss National Science Foundation (SNF; project number 3100170-114028).

REFERENCES


Edited by: H. J. Flint